Effect of Dual RAAS Blockade and Intensive BP Lowering on Risk of End-Stage Kidney Disease and Death in Autosomal Dominant Polycystic Kidney Disease: Long-term Follow-up of the HALT-PKD Trials

IF 9.4 1区医学 Q1 UROLOGY & NEPHROLOGY

American Journal of Kidney Diseases Pub Date : 2025-01-01 DOI:10.1053/j.ajkd.2024.06.020

Elaine Ku MD, MAS , Timothy P. Copeland PhD , Charles E. McCulloch PhD , Kaleab Z. Abebe PhD , Michel Chonchol MD , Ronald D. Perrone MD , Frederic F. Rahbari-Oskoui MD , Alan S.L. Yu MD , Theodore Steinman MD , Arlene Chapman MD , Mark J. Sarnak MD, MS

引用次数: 0

查看原文本刊更多论文

双重 RAAS 阻断和强化降压对常染色体显性遗传多囊肾病终末期肾病和死亡风险的影响：HALT-PKD试验的长期随访。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American Journal of Kidney Diseases 医学-泌尿学与肾脏学

CiteScore

20.40

自引率

2.30%

发文量

732

审稿时长

3-8 weeks

期刊介绍： The American Journal of Kidney Diseases (AJKD), the National Kidney Foundation's official journal, is globally recognized for its leadership in clinical nephrology content. Monthly, AJKD publishes original investigations on kidney diseases, hypertension, dialysis therapies, and kidney transplantation. Rigorous peer-review, statistical scrutiny, and a structured format characterize the publication process. Each issue includes case reports unveiling new diseases and potential therapeutic strategies.